<div id="readability-page-1"><p>HBK Sorce Advisory LLC acquired a new stake in  Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor  acquired 76,408 shares of the biotechnology company's stock, valued at approximately $2,823,000. HBK Sorce Advisory LLC owned about 0.06% of Arrowhead Pharmaceuticals at the end of the most recent quarter.</p><ul><li>Want Diversified Upside in Biotechnology? Check out LABU</li></ul><p>Other large investors have also bought and sold shares of the company. Resona Asset Management Co. Ltd. lifted its position in shares of  Arrowhead Pharmaceuticals by 8.7% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company's stock valued at $180,000 after buying an additional 900 shares during the last quarter.  Empowered Funds LLC lifted its holdings in  Arrowhead Pharmaceuticals by 6.9% during the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock valued at $194,000 after purchasing an additional 979 shares during the last quarter.  GAMMA Investing LLC lifted its holdings in  Arrowhead Pharmaceuticals by 64.4% during the third quarter. GAMMA Investing LLC now owns 2,626 shares of the biotechnology company's stock valued at $91,000 after purchasing an additional 1,029 shares during the last quarter.  KLP Kapitalforvaltning AS increased its stake in shares of  Arrowhead Pharmaceuticals by 5.2% in the second quarter. KLP Kapitalforvaltning AS now owns 24,300 shares of the biotechnology company's stock worth $384,000 after purchasing an additional 1,200 shares in the last quarter.  Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of  Arrowhead Pharmaceuticals by 29.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock worth $84,000 after purchasing an additional 1,214 shares in the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors. </p><h2>Arrowhead Pharmaceuticals Price Performance</h2><p>ARWR opened at $69.83 on Wednesday. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $9.49 billion, a P/E ratio of -872.77 and a beta of 1.28. The stock has a 50-day moving average price of $49.81 and a 200-day moving average price of $32.05. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $72.36. </p><h2>Arrowhead Pharmaceuticals News Summary</h2><p>Here are the key news stories impacting Arrowhead Pharmaceuticals this week:</p><ul>   <li><span>Positive Sentiment: </span>Company-scheduled investor activity in January could be a near-term catalyst: a KOL webinar on Jan 6 that will feature interim clinical data for obesity programs ARO‑INHBE and ARO‑ALK7, plus a presentation at the J.P. Morgan Healthcare Conference on Jan 12. Favorable interim data or a well-received JPM presentation could boost sentiment. <i></i><span>Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events</span></li>    <li><span>Neutral Sentiment: </span>Trading activity is below the stock’s average volume today, which can mute short-term moves; fundamental balance-sheet metrics remain strong (high current/quick ratios). No corporate guidance or major deals were announced. </li>    <li><span>Negative Sentiment: </span>Multiple insiders sold shares in late December — including CEO Christopher Anzalone and several directors — disclosed in SEC filings and covered by press. Insider sales can be interpreted negatively by some investors even though the CEO retains a very large position (millions of shares) and reported reductions were small percentage changes in holdings. See SEC filings and press coverage for details. <i></i><span>CEO Form 4</span> <i></i><span>Director Form 4</span> <i></i><span>Director Form 4</span> <i></i><span>Director Form 4</span> <i></i><span>Press: Insider Selling</span></li> </ul><h2>Analyst Ratings Changes</h2><p>ARWR has been the subject of several analyst reports. Bank of America raised their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, December 9th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Chardan Capital  reiterated a &#34;buy&#34; rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st. Morgan Stanley raised their target price on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Wednesday, November 26th. Finally, Royal Bank Of Canada upped their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned  a Buy rating, three have issued  a Hold rating and one  has assigned  a Sell rating to the company's stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $61.89.</p><p><b>Check Out Our Latest Research Report on ARWR</b></p><h2>Insider Transactions at Arrowhead Pharmaceuticals</h2><p>In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 10,000 shares of the company's stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $67.66, for a total transaction of $676,600.00. Following the completion of the sale, the director directly owned 33,600 shares in the company, valued at $2,273,376. This represents a 22.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director William D. Waddill sold 8,367 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $67.65, for a total value of $566,027.55. Following the completion of the transaction, the director owned 56,563 shares in the company, valued at approximately $3,826,486.95. This represents a 12.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 368,736 shares of company stock worth $23,670,228. Corporate insiders own  4.30% of the company's stock. </p><h2>About Arrowhead Pharmaceuticals</h2> (Free Report)<p>Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.  </p><p>The company's pipeline includes multiple candidates in various stages of development.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Arrowhead Pharmaceuticals</li><li>The boring AI play that could pay up to $4,290 monthly</li><li>Trump’s “real estate deal for America” explained</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>Trump Did WHAT??</li><li>A month before the crash</li></ul><p><strong>Want to see what other hedge funds are holding ARWR?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARWR

<p>HBK Sorce Advisory LLC acquired 76,408 shares of Arrowhead Pharmaceuticals, valued at approximately $2.82 million, during the 3rd quarter. This acquisition represents about 0.06% ownership in the company. Other institutional investors have also adjusted their positions in Arrowhead Pharmaceuticals. The stock's performance and analyst ratings indicate mixed sentiments, with some positive outlooks and insider sales noted.</p>

76,408 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by HBK Sorce Advisory LLC